What is Upstream Bio, Inc.'s stock issuance proceeds?

Upstream Bio, Inc. (UPB) reported stock issuance proceeds of $598K in Q1 2026.

What is the long-term trend for Upstream Bio, Inc.'s stock issuance proceeds?

Over 2 years (2023 to 2025), Upstream Bio, Inc.'s stock issuance proceeds has grown at a 339.5% compound annual growth rate (CAGR), from $118K to $2.28M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Upstream Bio, Inc. UPB Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Regeneron PharmaceuticalsREGN

$163.1M+169%

Aclaris TherapeuticsACRS

$151K—

Shattuck Labs, Inc.STTK

$20.56M—

SavaraSVRA

$45K-72.7%

AnaptysBio, Inc.ANAB

$14.02M+4,735%

Avalo TherapeuticsAVTX

$2.18M—

Other financials

Income statement

See full

Revenue$1.0M+82.7%

Operating income-$43.6M-36.2%

Net income-$40.6M-48.8%

EPS (diluted)-$0.75-47.1%

Balance sheet

See full

Cash & equivalents$96.7M+35.6%

Total debt$1.1M-34.5%

Total equity$304.0M-31.8%

Total assets$318.1M-30.3%

Cash flow

See full

Operating cash flow-$47.9M-16.2%

CapEx$54.0K-70.8%

Free cash flow-$30.7M-55.0%

Valuation

See full

Market cap$346.11M-40.9%

Enterprise value$250.5M-51.4%

P/S104.2×-151×

Profitability

See full

Operating margin-5,176.5%+1,764pp

Net margin-4,719%+2,752pp

Returns & leverage

See full

Return on equity-41.8%—

Debt / equity0×0.0×

Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Upstream Bio, Inc.'s stock issuance proceeds?: Upstream Bio, Inc. (UPB) reported stock issuance proceeds of $598K in Q1 2026.
What is the long-term trend for Upstream Bio, Inc.'s stock issuance proceeds?: Over 2 years (2023 to 2025), Upstream Bio, Inc.'s stock issuance proceeds has grown at a 339.5% compound annual growth rate (CAGR), from $118K to $2.28M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.